Repligen corp stock.

Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected]. Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 18.68% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...

Company profile page for Repligen Corp including stock price, company news, press releases, executives, board members, and contact information

What is Repligen Corp(RGEN)'s stock price today? The current price of RGEN is $160.21. The 52 week high of RGEN is $200.98 and 52 week low is $110.45. When is ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.× Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGERepligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.

The stock’s lowest price was $157.58 before closing at $157.00. Repligen Corp. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $200.98 on 02/16/23, while the lowest price for the same period was registered at $110.45 on 10/30/23.Repligen Corp (RGEN) will release its next earnings report on Feb 15, 2024. In the last quarter Repligen Corp reported $0.165 EPS in relation to $0.23 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the ...Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts …11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price.Item 7.01 Regulation FD Disclosure. On April 12, 2023, Repligen Corporation (the "Company") made available an Investor Presentation relating to the FlexBiosys Transaction described in Item 8.01 of this 8-K. A copy of this Investor Presentation is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1.Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp., which was founded by Alexander G., provides bioprocessing technologies and services utilized in producing biological drugs. ... With institutions owning 91% of its stock, it’s clear that Repligen is attracting some serious attention from experienced and savvy investors who see its potential for growth in the biotech sector ...Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

12 thg 9, 2023 ... ... Repligen.” About Repligen Corporation Repligen Corporation is a ... Stock RGEN logo. Repligen Corp. NASDAQ:RGEN. RGEN Latest News. Oct 17, 2023.

In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...RGEN Repligen Corp. 161.78 1.57 ( 0.98%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Apr 25, 2023 · Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today. Saint Barbara is the patron saint of Marine artillerymen. She is also recognized by Marine Corps Aviation ordnancemen. Saint Michael is the patron saint of the armed forces.Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected]. On average, Wall Street analysts predict that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a ...As of February 13, 2023, Repligen Corp had a $10.2 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $331.8 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0.Item 7.01 Regulation FD Disclosure. On April 12, 2023, Repligen Corporation (the "Company") made available an Investor Presentation relating to the FlexBiosys Transaction described in Item 8.01 of this 8-K. A copy of this Investor Presentation is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1.

Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …

Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp. (RGEN) current stock price is $159.46 with a 24-hour trading volume of 392.47K. The stock decreased by -1.43% in the last 24 hours and rose by +33.35% in the past month. Looking at the chart, RGEN stock price is below the pivot point level of $161.1, suggesting a potential bearish market, if it continues to fall close to the support level of …Repligen Corp. stock grades by Barron's. View RGEN fundamental and sentiment analysis powered by MarketGrader.CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Stock analysis for Repligen Corp (R2GE34:B3 Day) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Repligen Corp (RGEN-1.40%) Q3 ... 10 stocks we like better than Repligen When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for ...While Repligen Corporation (NASDAQ:RGEN) might not be the most widely known stock at the moment, it received a lot of attention from a substantial price increase on the NASDAQGS over the last few ...Apr 21, 2020 · However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ... Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected]. Repligen Corporation Prices Public Offering of Shares of Common Stock. 6/27/2017. Summary. WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation ...

Oct 13, 2023 · Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ... Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ...Instagram:https://instagram. nyseamerican utgvgt holdingstemu stock forecastpaper trading futures Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B. home builder stocks listtop rated forex brokers Third quarter 2023 adjusted gross profit was $59.3 million, a 48% decrease year-over-year and nearly $60 million of lower revenue, and on a lower adjusted gross margin, which was 42% in the third ... home loan without tax returns As President and CEO at REPLIGEN CORP , Tony J. Hunt made $7,713,930 in total compensation. Of this total $800,000 was received as a salary, $785,440 was received as a bonus, $1,623,698 was received in stock options, $4,499,792 was awarded as stock and $5,000 came from other types of compensation. This information is according to proxy ...Get Repligen Corp (RGEN.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Repligen Corp RGEN.OQ. Official Data Partner ...RGEN - Repligen Corp. - Stock screener for investors and traders, financial visualizations.